Triumph Capital Management’s Biogen BIIB Stock Holding History

Triumph Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$183	Buy	+1	New	+$184	﹤0.01%	1770

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Triumph Capital Management's BIIB Position: Q1 2026 in Review

Triumph Capital Management opened a new position in Biogen (BIIB) in Q1 2026: 1 share worth $183. The stake represents ﹤0.01% of the portfolio and ranks #1770 among its holdings.

1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Triumph Capital Management held 1 share of Biogen worth $183 as of Q1 2026.
Biogen was a new Triumph Capital Management position in Q1 2026.
Biogen made up ﹤0.01% of Triumph Capital Management's portfolio in Q1 2026, its #1770 holding.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.